According to Pammoli, screening has improved (attrition rates decreasing in all phases of clinicaltrials) and focus has shifted to oncology, rare diseases and advanced therapies. Find out more here.
According to Pammoli, screening has improved (attrition rates decreasing in all phases of clinicaltrials) and focus has shifted to oncology, rare diseases and advanced therapies. Find out more here.